Predictors of infusion reactions during infliximab treatment in patients with arthritis 英文参考文献.docVIP

Available online /content/8/4/R131 Research article Open Access Vol 8 No 4 Predictors of infusion reactions during infliximab treatment in patients with arthritis Meliha C Kapetanovic1, Lotta Larsson1, Lennart Truedsson2, Gunnar Sturfelt1, Tore Saxne1 and Pierre Geborek1 1Department of Rheumatology, Lund University Hospital, Lund, Sweden 2Department of Clinical Microbiology and Immunology, Lund University Hospital, Lund, Sweden Corresponding author: Meliha C Kapetanovic, meliha.crnkic@med.lu.se Received: 27 Apr 2006 Revisions requested: 24 May 2006 Revisions received: 10 Jul 2006 Accepted: 26 Jul 2006 Published: 26 Jul 2006 Arthritis Research Therapy 2006, 8:R131 (doi:10.1186/ar2020) This article is online at: /content/8/4/R131 ? 2006 Kapetanovic et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract In the present study we evaluated the impact of baseline antinuclear antibody (ANA) status and use of methotrexate on development of infliximab-related infusion reactions in patients with rheumatoid arthritis (RA) or spondylarthropathies (SpAs), including psoriatic arthritis. All patients with RA (n = 213) or SpA (n = 76) treated with infliximab during the period 1999– 2005 at the Department of Rheumatology in Lund, Sweden were included. ANAs were present in 28% and 25% of RA and SpA patients, respectively. Because of differences in baseline characteristics, we used a binary logistic regression model to calculate odds ratios (ORs), adjusting for age, sex and prednisolone dosage. Altogether 21% of patients with RA and 13% of patients with SpA developed infusion reactions (P = 0.126). The OR for development of infusion reactions in RA patients with baseline ANA posi